Clinical utility of ramucirumab in advanced gastric cancer.

Biologics · 2015 · PMC4589126 · PMID 26451083

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

63 However, a comprehensive evaluation of baseline VEGF-A levels in several Phase III trials of colorectal, lung, and renal cancers showed a trend toward an adverse prognostic effect with higher VEGF-A levels but showed no predictive value for treatment with bevacizumab. 64 We eagerly await biomarker analysis from the studies of ramucirumab.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.